Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Abstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab duri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d357221a247457589d886c5e06e1e3d
record_format	dspace
spelling	oai:doaj.org-article:2d357221a247457589d886c5e06e1e3d2021-12-02T16:10:32ZBevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients10.1038/s41698-021-00197-w2397-768Xhttps://doaj.org/article/2d357221a247457589d886c5e06e1e3d2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00197-whttps://doaj.org/toc/2397-768XAbstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.Yves BoucherAshwin S. KumarJessica M. PosadaEvisa GjiniKathleen PfaffMikel LipschitzAna LakoDan G. DudaScott J. RodigF. Stephen HodiRakesh K. JainNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yves Boucher Ashwin S. Kumar Jessica M. Posada Evisa Gjini Kathleen Pfaff Mikel Lipschitz Ana Lako Dan G. Duda Scott J. Rodig F. Stephen Hodi Rakesh K. Jain Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
description	Abstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.
format	article
author	Yves Boucher Ashwin S. Kumar Jessica M. Posada Evisa Gjini Kathleen Pfaff Mikel Lipschitz Ana Lako Dan G. Duda Scott J. Rodig F. Stephen Hodi Rakesh K. Jain
author_facet	Yves Boucher Ashwin S. Kumar Jessica M. Posada Evisa Gjini Kathleen Pfaff Mikel Lipschitz Ana Lako Dan G. Duda Scott J. Rodig F. Stephen Hodi Rakesh K. Jain
author_sort	Yves Boucher
title	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
title_short	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
title_full	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
title_fullStr	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
title_full_unstemmed	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
title_sort	bevacizumab improves tumor infiltration of mature dendritic cells and effector t-cells in triple-negative breast cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
work_keys_str_mv	AT yvesboucher bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT ashwinskumar bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT jessicamposada bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT evisagjini bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT kathleenpfaff bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT mikellipschitz bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT analako bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT dangduda bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT scottjrodig bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT fstephenhodi bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients AT rakeshkjain bevacizumabimprovestumorinfiltrationofmaturedendriticcellsandeffectortcellsintriplenegativebreastcancerpatients
_version_	1718384401270702080

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Ejemplares similares